Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics.
Karagianis
James L
JL
Dunayevich
Eduardo
E
D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001569:Benzodiazepines / Q000009:adverse effects / Q000627:therapeutic use; D015982:Bias; D015415:Biomarkers / Q000097:blood*; D003324:Coronary Artery Disease / Q000378:metabolism*; D003430:Cross-Sectional Studies; D005215:Fasting / Q000097:blood / Q000378:metabolism; D006801:Humans; D024821:Metabolic Syndrome / Q000139:chemically induced / Q000378:metabolism*; D000077152:Olanzapine; D012107:Research Design / Q000592:standards; D012307:Risk Factors; D018967:Risperidone / Q000009:adverse effects / Q000627:therapeutic use
D014150:Antipsychotic Agents; D015415:Biomarkers; D001569:Benzodiazepines; D018967:Risperidone; D000077152:Olanzapine